Top Chinese drugmaker Hengrui soars in Hong Kong trading debut

Quick Summary:

Hengrui’s debut, which comes on the heels of CATL's blockbuster Hong Kong premiere, builds on the city's hot listings market.

Its first attempt at FDA approval was rejected twice, and other drugs are still years away from potential overseas registration.

But the company has yet to win an approval for any of its branded drugs outside of China.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Amber Tong, Bloomberg

Category: EconomyBusiness

Markets: United StatesChinaHong Kong

Topics: Bloomberg Editor's Picks Pharmaceutical Industry Featured IPOs

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-05-23 @ 07:24:27 (15 hours ago)

News Timezone: GMT +8:00

News Source URL: fortune.com

Language: English

Article Length: 339 words

Reading Time: 2 minutes read

Sentences: 4 lines

Sentence Length: 85 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Fortune

News ID: 28922318

View Article Analysis

About Fortune

Main Topics: EconomyBusiness

Official Website: fortune.com

Update Frequency: 32 posts per day

Year Established: 1929

Headquarters: United States

News Last Updated: 8 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #95

Publisher Details

Frequently Asked Questions